$14.25
2.13% today
NYSE, Nov 26, 09:23 am CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Target price 2024 - Analyst rating & recommendation

Arcus Biosciences Classifications & Recommendation:

Buy
73%
Hold
27%

Arcus Biosciences Price Target

Target Price $32.80
Price $14.56
Potential
Number of Estimates 10
10 Analysts have issued a price target Arcus Biosciences 2025 . The average Arcus Biosciences target price is $32.80. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 8 Analysts recommend Arcus Biosciences to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arcus Biosciences stock has an average upside potential 2025 of . Most analysts recommend the Arcus Biosciences stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 117.00 260.92
4.46% 123.01%
EBITDA Margin -276.92% -116.85%
16.60% 57.80%
Net Margin -324.55% -116.64%
7.08% 64.06%

9 Analysts have issued a sales forecast Arcus Biosciences 2024 . The average Arcus Biosciences sales estimate is

$261m
Unlock
. This is
0.79% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$272m 3.42%
Unlock
, the lowest is
$244m 7.22%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $117m 4.46%
2024
$261m 123.01%
Unlock
2025
$226m 13.28%
Unlock
2026
$246m 8.87%
Unlock
2027
$260m 5.60%
Unlock
2028
$635m 144.29%
Unlock

4 Analysts have issued an Arcus Biosciences EBITDA forecast 2024. The average Arcus Biosciences EBITDA estimate is

$-305m
Unlock
. This is
6.60% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-257m 10.08%
Unlock
, the lowest is
$-335m 17.08%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-324m 21.80%
2024
$-305m 5.90%
Unlock
2025
$-402m 31.80%
Unlock
2026
$-441m 9.84%
Unlock

EBITDA Margin

2023 -276.92% 16.60%
2024
-116.85% 57.80%
Unlock
2025
-177.59% 51.98%
Unlock
2026
-179.18% 0.90%
Unlock

10 Arcus Biosciences Analysts have issued a net profit forecast 2024. The average Arcus Biosciences net profit estimate is

$-304m
Unlock
. This is
5.59% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-224m 22.22%
Unlock
, the lowest is
$-357m 23.81%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-380m 11.86%
2024
$-304m 19.85%
Unlock
2025
$-395m 29.76%
Unlock
2026
$-400m 1.27%
Unlock
2027
$-427m 6.76%
Unlock
2028
$-118m 72.44%
Unlock

Net Margin

2023 -324.55% 7.08%
2024
-116.64% 64.06%
Unlock
2025
-174.53% 49.63%
Unlock
2026
-162.36% 6.97%
Unlock
2027
-164.15% 1.10%
Unlock
2028
-18.52% 88.72%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -4.15 -3.33
11.86% 19.76%
P/E negative
EV/Sales 1.16

10 Analysts have issued a Arcus Biosciences forecast for earnings per share. The average Arcus Biosciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.33
Unlock
. This is
5.71% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.45 22.22%
Unlock
, the lowest is
$-3.90 23.81%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-4.15 11.86%
2024
$-3.33 19.76%
Unlock
2025
$-4.32 29.73%
Unlock
2026
$-4.37 1.16%
Unlock
2027
$-4.67 6.86%
Unlock
2028
$-1.29 72.38%
Unlock

P/E ratio

Current -4.62 31.62%
2024
-4.38 5.19%
Unlock
2025
-3.37 23.06%
Unlock
2026
-3.33 1.19%
Unlock
2027
-3.12 6.31%
Unlock
2028
-11.32 262.82%
Unlock

Based on analysts' sales estimates for 2024, the Arcus Biosciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.15 47.49%
2024
1.16 0.45%
Unlock
2025
1.33 15.30%
Unlock
2026
1.22 8.15%
Unlock
2027
1.16 5.30%
Unlock
2028
0.47 59.07%
Unlock

P/S ratio

Current 5.07 42.40%
2024
5.11 0.80%
Unlock
2025
5.89 15.31%
Unlock
2026
5.41 8.14%
Unlock
2027
5.12 5.30%
Unlock
2028
2.10 59.06%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today